Group 1 - The flu sector experienced a significant surge on January 26, with companies such as Maike Bio, Cape Bio, Zhijiang Bio, and Hualan Vaccine hitting a 20% limit up, while others like Da'an Gene, Te Yi Pharmaceutical, and Lukan Pharmaceutical also reached their limit up [1] - Notable increases were observed in companies like Zhi Fei Bio, Wanfu Bio, CanSino, and Watson Bio, which rose over 10% [1] Group 2 - In West Bengal, India, five confirmed cases of Nipah virus infection have been reported, including healthcare workers, leading to nearly 100 individuals being asked to stay in isolation [3] - The Nipah virus can severely affect the lungs and brain, with symptoms including fever, headache, drowsiness, confusion, and coma, and a mortality rate that can exceed 40% [3] - Thailand's Civil Aviation Authority announced comprehensive screening for flights from West Bengal starting January 26 to prevent the Nipah virus from entering the country, with adjustments to be made based on the evolving situation [3]

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

Market Overview - The Shanghai Composite Index closed at 4141.01 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares reached 22,631.30 billion yuan [1] Stocks Breaking Annual Line - A total of 44 A-shares have broken above the annual line today, with notable stocks including Tongguan Mining Construction, Maike Biological, and Jiuliang Co., with deviation rates of 17.26%, 8.94%, and 8.33% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Laofengxiang, Shench Pharmaceutical, and Tuo Xin Pharmaceutical [1] Top Stocks by Deviation Rate - The top three stocks with the highest deviation rates are: - Tongguan Mining Construction: 21.40% increase, latest price 26.04 yuan, deviation rate 17.26% [1] - Maike Biological: 11.83% increase, latest price 13.23 yuan, deviation rate 8.94% [1] - Jiuliang Co.: 10.92% increase, latest price 31.28 yuan, deviation rate 8.33% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Binhang Technology: 7.30% increase, latest price 165.50 yuan, deviation rate 6.84% [1] - New Ganjing: 6.13% increase, latest price 25.81 yuan, deviation rate 5.30% [1] - Kangpu Chemical: 5.79% increase, latest price 20.64 yuan, deviation rate 5.05% [1]

有投资者在互动平台向迈克生物提问："贵公司主推的智慧化实验室，给投资者感觉像是一体化，系统 化，智能化提升医院检验中心。请问，如果医院使用贵公司产品改造升级自己的检验中心，能享受国家 和当地政府财政补贴吗？有以旧换新补贴吗？还是有其他的财政补贴支持？国家和当地政府升级基础医 疗器械补贴能享受到吗？" 针对上述提问，迈克生物回应称："尊敬的投资者，您好！因为智慧化实验室作为医院检验科的新业态 产品，不适用于传统设备的置换补贴概念；由于各地财政能力与评审周期不同，且医院须完成相关论 证、评审及申报，各医院具体情况差异较大。现阶段获得补贴的订单占比仍然较低，对公司整体业绩影 响有限。感谢您的关注与支持！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

证券代码：300463 证券简称：迈克生物 公告编号：2026-003 迈克生物股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司第六届董事会第二次会议、第六届监事会第二次会议审议通过了 《关于继续使用部分闲置募集资金进行现金管理的议案》，为提高暂时闲置募集资金的使用效 率，增加资金收益，在保证募集资金投资项目建设和募集资金正常使用的情况下，同意使用不 超过人民币6,000万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、满 足保本要求的理财产品，自公司第六届董事会第二次会议审议通过之日起十二个月内有效，在 上述使用期限及额度内，资金可以循环滚动使用。闲置募集资金现金管理到期后将及时归还至 募集资金专户，同时授权公司董事长行使相关投资决策权，财务负责人办理具体相关事宜。公 司已于2025年3月7日在巨潮资讯网刊登了《关于继续使用部分闲置募集资金进行现金管理的公 告》（公告编号：2025-012）。 近日，公司使用部分闲置募集资金购买的理财产品已到期赎回，并继续使用人民币 ...

证券代码:300463 证券简称:迈克生物 公告编号:2026-002 迈克生物股份有限公司（以下简称"公司"）于近日收到四川省药品监督管理局颁发的《医 疗器械注册证》（体外诊断试剂），具体情况如下： 一、产品注册证具体情况 | 产品名称 | 注册证书 编号 | 注册 | | | 注册证有效期 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 类别 | | | | | | | 糖化血红蛋白测 定试剂盒（高效液 | 川械注准 | Ⅱ | 2026 | 年 1 | 月 8 | 日至 | 本品用于体外定量检测人体全血样本中 | | 相色谱法） | 20262400003 | | 2031 | 年 | 月 1 | 日 7 | 糖化血红蛋白的含量。 | | 糖化血红蛋白质 | 川械注准 | | | 年 | 月 | 日至 | 本品需配套本公司生产的糖化血红蛋白 | | 控品 | 20262400004 | Ⅱ | 2026 2031 | 1 年 | 8 月 1 | 日 7 | 测定试剂盒（高效液相色谱法）使用， 用于糖化血红蛋白项目的质量 ...

Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration [1] - The registered product is a cross-matching blood quality control product [1]

Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration for its product, a cross-matching blood quality control reagent [1]

Core Viewpoint - The company, Maike Biological (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its new product, cross-matching blood quality control products, which enhances its product portfolio and market competitiveness [1] Group 1 - The newly registered product is intended for quality control in manual and fully automated blood type analysis systems during cross-matching tests [1] - The introduction of this product is expected to positively impact the company's market expansion and future operations [1] - The registration certificate enriches the company's product offerings, contributing to its overall market competitiveness [1]

Core Viewpoint - The company announced that its cross-matching quality control product has received a medical device registration certificate from the National Medical Products Administration, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The new product is designed for use with the company's anti-human globulin (anti-IgG+C3d) testing card and is intended for quality control in manual and fully automated blood type analysis systems [1] - The product is specifically for clinical testing and is not intended for blood source screening [1] Group 2: Market Impact - The registration certificate for the new product is expected to positively influence the company's market expansion and future operations [1] - The actual sales performance of the registered product will depend on future marketing efforts, and the impact on the company's future revenue remains unpredictable [1]